The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study

埃索美拉唑 医学 格尔德 内科学 随机对照试验 不利影响 胃肠病学 入射(几何) 食管炎 临床终点 回流 疾病 物理 光学
作者
Qianjun Zhuang,Aijun Liao,Qingling He,Chengxia Liu,Changqing Zheng,Xing Li,Youli Liu,Han Ma,Side Liu,Yan Zhang,Rong Lin,Huixin Chen,Min Deng,Yanping Tang,Chiyi He,Weijie Dai,Haitao Tang,Lei Gong,LI Liang-ping,Baohong Xu
出处
期刊:Journal of Gastroenterology and Hepatology [Wiley]
卷期号:39 (4): 658-666 被引量:13
标识
DOI:10.1111/jgh.16471
摘要

Abstract Background and Aim Fexuprazan is a novel potassium‐competitive acid blocker (P‐CAB). This study aimed to explore the noninferior efficacy and safety of fexuprazan to esomeprazole in treating erosive esophagitis (EE). Methods This was a phase III, randomized, double‐blind multicenter study. Patients with endoscopically confirmed EE were randomized to receive fexuprazan 40 mg or esomeprazole 40 mg once a daily for 4–8 weeks. The healing rates of EE, symptom response, GERD‐health‐related quality life (GERD‐HRQL), and treatment‐emergent adverse events (TEAEs) were compared between fexuprazan group and esomeprazole group. Results A total of 332 subjects were included in full analysis set (FAS) and 311 in per‐protocol set (PPS). The healing rates of fexuprazan and esomeprazole groups at 8 weeks were 88.5% (146/165) and 89.0% (145/163), respectively, in FAS and 97.3% (145/149) and 97.9% (143/146), respectively, in PPS. Noninferiority of fexuprazan compared with esomeprazole according to EE healing rates at 8 weeks was demonstrated in both FAS and PPS analysis. No significant difference was found between groups in EE healing rates at 4 weeks, symptom responses, and changes of GERD‐HRQL. The incidence of drug‐related AEs was 19.4% (32/165) in fexuprazan arm and 19.6% (32/163) in esomeprazole arm. Conclusion This study demonstrated noninferior efficacy of fexuprazan to esomeprazole in treating EE. The incidence of TEAEs was similar between fexuprazan and esomeprazole. Trial registration number NCT05813561.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
123456完成签到,获得积分10
1秒前
1秒前
852应助Engen采纳,获得10
2秒前
嘻嘻嘻完成签到,获得积分10
2秒前
小何完成签到,获得积分10
2秒前
2秒前
zhaoyuyuan发布了新的文献求助10
3秒前
淡淡的凝冬完成签到,获得积分10
3秒前
Owen应助五山第一院士采纳,获得10
3秒前
spenley完成签到,获得积分10
3秒前
善良鱼哟发布了新的文献求助10
3秒前
white完成签到,获得积分10
4秒前
结实红酒发布了新的文献求助10
4秒前
DHMO完成签到,获得积分10
5秒前
量子星尘发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
zhui发布了新的文献求助10
5秒前
搜集达人应助可爱皮皮虾采纳,获得10
5秒前
6秒前
6秒前
丰富觅儿完成签到,获得积分10
6秒前
6秒前
upupup发布了新的文献求助10
6秒前
烟花应助我请问呢采纳,获得10
7秒前
7秒前
7秒前
7秒前
所所应助细心的梦芝采纳,获得10
7秒前
Arzu完成签到,获得积分10
7秒前
queer发布了新的文献求助10
8秒前
科研通AI5应助dong采纳,获得10
9秒前
queer发布了新的文献求助10
9秒前
9秒前
10秒前
spirit发布了新的文献求助10
10秒前
10秒前
英姑应助kkt采纳,获得10
11秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974358
求助须知:如何正确求助?哪些是违规求助? 3518706
关于积分的说明 11195521
捐赠科研通 3254897
什么是DOI,文献DOI怎么找? 1797614
邀请新用户注册赠送积分活动 877011
科研通“疑难数据库(出版商)”最低求助积分说明 806128